Eywa Pharma Inc. received 180-day exclusivity for the ANDA211610 approval of acetaminophen and codeine phosphate oral dosage form on June 27, 2019, signaling heighted competitive pressure on the market and potentially catalyzing discounts for the widely used generic analgesic.